# A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range

> **NCT06041217** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 242 (actual)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06041217
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-15
- **Primary completion:** 2025-04-02
- **Final completion:** 2025-05-07
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06041217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06041217, "A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06041217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*